Protocol No: | ECCT/23/09/02 | Date of Protocol: | 06-02-2023 |
Study Title: |
A PHASE IB, RANDOMIZED, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF CROVALIMAB FOR THE MANAGEMENT OF ACUTE UNCOMPLICATED VASO‑OCCLUSIVE EPISODES (VOE) IN PATIENTS WITH SICKLE CELL DISEASE (SCD)
|
Study Objectives: | This study will evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of crovalimab compared with placebo for the management of acute uncomplicated VOE in patients with SCD.
- Incidence and severity of adverse events, with severity determined according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events, Version 5.0 (CTCAE v5.0) - Change from baseline in targeted vital signs and clinical laboratory test results - Incidence and severity of infusion-related reactions and hypersensitivity
- Serum concentrations of crovalimab over time
- Relationships between drug exposure and pharmacodynamics, efficacy or safety endpoints of crovalimab (patients randomized to crovalimab)
- Change over time in PD biomarkers, including total complement activity (CH50) measured by a LIA, total and free complement component 5 (C5) concentration, and sC5b-9 concentration
- Confirmed decrease in pain score of at least 2 points from the maximal pre-dose pain score, that is sustained in at least two pain assessments
conducted a minimum of 6 hours apart from each other (as measured with the Numerical Rating Scale [NRS] on a 010 scale) AND transition to oral pain
medications for a minimum of 6 hours after the completion of the last dose of
parenteral opioids, OR
- Readiness for hospital discharge (as defined by the patient’s assessment that pain can be managed at home AND agreement from investigator), OR
- Hospital discharge
- Prevalence of anti-drug antibodies (ADAs) at baseline and incidence of ADAs during the study (patients randomized to crovalimab)
- Potential effects of ADAs on efficacy, safety, or PK endpoints
- Observed value and change over time in exploratory biomarkers including but not limited to markers of hemolysis, immune cell activation, inflammation, endothelial/vascular damage, and end-organ injury
- Relationship between biomarkers in blood and efficacy, safety, pharmacokinetics, immunogenicity, or other biomarker endpoints
|
Laymans Summary: |
This randomized, multicenter, placebo-controlled, double-blinded Phase Ib study is designed to evaluate the safety (primary study objective), pharmacokinetics, pharmacodynamics, and efficacy of crovalimab compared with placebo for the management of an acute uncomplicated VOE in adult and adolescent patients with SCD.
This study will enroll approximately 30 patients (at approximately 10-15 sites globally), aged 12-55 years old and more than or equal to 40 kg, with SCD genotype of HbSS or HbS beta zero thalassemia, presenting to the ER/ED or acute medical facility with an acute uncomplicated VOE (as defined in Section 2.4.1 of the protocol).
Patients who present with acute complications such as ACS, priapism, hepatic or splenic sequestration etc., or present with pain atypical of or unrelated to an acute uncomplicated VOE will be excluded at screening.
Complications of the VOE that develop after study treatment administration and during hospitalization will be documented. Patients who develop complications after screening, but before study treatment administration, may no longer be eligible.
|
Abstract of Study: |
PROTOCOL NUMBER: BO42452
STUDY NAME: Crosswalk A
VERSION NUMBER: 3 (Africa)
TEST COMPOUND(S): Crovalimab (RO7112689)
This randomized, multicenter, placebo-controlled, double-blinded Phase Ib study is designed to evaluate the safety (primary study objective), pharmacokinetics, pharmacodynamics, and efficacy of crovalimab compared with placebo for the management of an acute uncomplicated VOE in adult and adolescent patients with SCD.
This study will enroll approximately 30 patients (at approximately 10-15 sites globally), aged 12-55 years old and more than or equal to 40 kg, with SCD genotype of sickle cell anemia (HbSS) or SCD genotype of sickle cell beta zero thalassemia, presenting to the emergency room/emergency department (ER/ED) or acute medical facility with an acute uncomplicated VOE, defined as an acute episode of pain with no other medically determined cause, that requires admission to a hospital/acute medical facility and treatment with parenteral opioid analgesics.
A 2-step process for screening procedures is encouraged to preliminarily identify and consent patients for the study prior to VOE presentation:
NUMBER OF PATIENTS
Approximately 30 patients (20 on crovalimab and 10 on placebo).
END OF STUDY
The end of this study is defined as the date when the last patient’s last visit occurs, or the date at which the last data point is received from the last patient on study, whichever occurs later. The end of the study is expected to occur approximately 322 days or approximately 10.5 months after the last patient is enrolled.
LENGTH OF STUDY
Assuming an enrollment period of approximately 2 years, the total length of the study, from screening of the first patient in the ER/ED or acute medical facility to the end of the study, is expected to be approximately 3 years.
|